Suppr超能文献

丝裂原活化蛋白激酶激酶激酶1激活前列腺癌中雄激素受体依赖性转录和细胞凋亡。

Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer.

作者信息

Abreu-Martin M T, Chari A, Palladino A A, Craft N A, Sawyers C L

机构信息

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90095, USA.

出版信息

Mol Cell Biol. 1999 Jul;19(7):5143-54. doi: 10.1128/MCB.19.7.5143.

Abstract

Mitogen-activated protein (MAP) kinases phosphorylate the estrogen receptor and activate transcription from estrogen receptor-regulated genes. Here we examine potential interactions between the MAP kinase cascade and androgen receptor-mediated gene regulation. Specifically, we have studied the biological effects of mitogen-activated protein kinase kinase kinase 1 (MEKK1) expression in prostate cancer cells. Our findings demonstrate that expression of constitutively active MEKK1 induces apoptosis in androgen receptor-positive but not in androgen receptor-negative prostate cancer cells. Reconstitution of the androgen receptor signaling pathway in androgen receptor-negative prostate cancer cells restores MEKK1-induced apoptosis. MEKK1 also stimulates the transcriptional activity of the androgen receptor in the presence or absence of ligand, whereas a dominant negative mutant of MEKK1 impairs activation of the androgen receptor by androgen. These studies demonstrate an unanticipated link between MEKK1 and hormone receptor signaling and have implications for the molecular basis of hormone-independent prostate cancer growth.

摘要

丝裂原活化蛋白(MAP)激酶使雌激素受体磷酸化并激活雌激素受体调控基因的转录。在此,我们研究丝裂原活化蛋白激酶级联反应与雄激素受体介导的基因调控之间的潜在相互作用。具体而言,我们研究了丝裂原活化蛋白激酶激酶激酶1(MEKK1)在前列腺癌细胞中的表达所产生的生物学效应。我们的研究结果表明,组成型活性MEKK1的表达在雄激素受体阳性的前列腺癌细胞中诱导凋亡,但在雄激素受体阴性的前列腺癌细胞中则不然。在雄激素受体阴性的前列腺癌细胞中重建雄激素受体信号通路可恢复MEKK1诱导的凋亡。无论有无配体,MEKK1均能刺激雄激素受体的转录活性,而MEKK1的显性负性突变体则会损害雄激素对雄激素受体的激活作用。这些研究证明了MEKK1与激素受体信号传导之间存在意想不到的联系,并对激素非依赖性前列腺癌生长的分子基础具有重要意义。

相似文献

引用本文的文献

4
Androgen Signaling in Prostate Cancer: When a Friend Turns Foe.前列腺癌中的雄激素信号传导:当朋友变成敌人时。
Endocr Metab Immune Disord Drug Targets. 2025;25(1):37-56. doi: 10.2174/0118715303313528240523101940.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验